Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avant Diagnostics, IncAVDX · Entity 148455 | Director | August 20, 2018 | October 10, 2018 |
| Chiron Real Estate Inc.GMRE · Entity 5421 | Director · Chairman, President and CEO | February 26, 2025 | February 27, 2025 |
| IMAC Holdings, Inc.BACK · Entity 81795 | Director | December 31, 2024 | January 02, 2025 |
| THERALINK TECHNOLOGIES, INC.THER · Entity 94673 | Director | November 29, 2022 | February 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avant Diagnostics, Inc
Report date August 20, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 230,000 |
Reported balance
After 2018-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-20 · Grant · Acquired 50,000 · Balance 230,000 F1: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer.
Chiron Real Estate Inc.
Report date February 26, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| LTIP Unit (Right to Buy)SEC Table II · derivative / convertible security | Direct | 745,015 |
Reported balance
After 2025-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-26 · Grant · Acquired 23,613 · Balance 745,015 F1: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 26, 2025, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2024 and February 26, 2025 and 50% of the LTIP Units will vest on February 26, 2026 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 26, 2025, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2024 and February 26, 2025 and 50% of the LTIP Units will vest on February 26, 2026 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date.
F2: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
IMAC Holdings, Inc.
Report date December 31, 2024 · Filed January 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, no par valueSEC Table I · non-derivative | Direct | 3,333 |
Reported balance
After 2024-12-31 transaction · row 1
1 source rowRow 1 · 2024-12-31 · Grant · Acquired 3,333 · Balance 3,333 F1: The Reporting Person received shares of common stock granted under the Issuer's 2018 Incentive Compensation Plan constituting annual board compensation with respect Reporting Person's service as a director during 2024. |
| Series C-1 Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.56 | Direct | 265 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 265 F2: The conversion price is subject to adjustment from time to time. F3: The shares of Series C-1 Preferred Convertible Preferred Stock, par value $0.001 per share (the "Series C-1 Preferred Stock") are immediately convertible into shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock"). F4: The Series C-1 Preferred Stock is perpetual and therefore has no expiration. F5: Currently, holders of Series C-1 Preferred Stock receive quarterly dividends in the form of an increase in the stated value of their shares of Series C-1 Preferred Stock until the Issuer obtains stockholder approval to issue dividends in the form of shares of Common Stock. Accordingly, the number of shares of Common Stock underlying the Series C-1 Preferred Stock held by the Reporting Person changes quarterly. However, the Series C-1 Preferred Stock is subject to a beneficial ownership cap that prohibits the conversion of the Series C-1 Preferred Stock into shares of Common Stock to the extent that such conversion would cause the reporting person's beneficial ownership, together with its affiliates, to exceed 9.99%. |
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.64 | Direct | 1,641 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,641 F2: The conversion price is subject to adjustment from time to time. F6: The shares of Series E Preferred Convertible Preferred Stock, par value $0.001 per share (the "Series E Preferred Stock") are immediately convertible into shares of the Common Stock. F7: The Series E Preferred Stock is perpetual and therefore has no expiration. F8: Currently, holders of Series E Preferred Stock receive quarterly dividends in the form of an increase in the stated value of their shares of Series E Preferred Stock until the Issuer obtains stockholder approval to issue dividends in the form of shares of Common Stock. Accordingly, the number of shares of Common Stock underlying the Series E Preferred Stock held by the Reporting Person changes quarterly. However, the Series E Preferred Stock is subject to a beneficial ownership cap that prohibits the conversion of the Series E Preferred Stock into shares of Common Stock to the extent that such conversion would cause the reporting person's beneficial ownership, together with its affiliates, to exceed 9.99%. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received shares of common stock granted under the Issuer's 2018 Incentive Compensation Plan constituting annual board compensation with respect Reporting Person's service as a director during 2024.
F2: The conversion price is subject to adjustment from time to time.
F3: The shares of Series C-1 Preferred Convertible Preferred Stock, par value $0.001 per share (the "Series C-1 Preferred Stock") are immediately convertible into shares of the Issuer's common stock, par value $0.001 per share (the "Common Stock").
F4: The Series C-1 Preferred Stock is perpetual and therefore has no expiration.
F5: Currently, holders of Series C-1 Preferred Stock receive quarterly dividends in the form of an increase in the stated value of their shares of Series C-1 Preferred Stock until the Issuer obtains stockholder approval to issue dividends in the form of shares of Common Stock. Accordingly, the number of shares of Common Stock underlying the Series C-1 Preferred Stock held by the Reporting Person changes quarterly. However, the Series C-1 Preferred Stock is subject to a beneficial ownership cap that prohibits the conversion of the Series C-1 Preferred Stock into shares of Common Stock to the extent that such conversion would cause the reporting person's beneficial ownership, together with its affiliates, to exceed 9.99%.
F6: The shares of Series E Preferred Convertible Preferred Stock, par value $0.001 per share (the "Series E Preferred Stock") are immediately convertible into shares of the Common Stock.
F7: The Series E Preferred Stock is perpetual and therefore has no expiration.
F8: Currently, holders of Series E Preferred Stock receive quarterly dividends in the form of an increase in the stated value of their shares of Series E Preferred Stock until the Issuer obtains stockholder approval to issue dividends in the form of shares of Common Stock. Accordingly, the number of shares of Common Stock underlying the Series E Preferred Stock held by the Reporting Person changes quarterly. However, the Series E Preferred Stock is subject to a beneficial ownership cap that prohibits the conversion of the Series E Preferred Stock into shares of Common Stock to the extent that such conversion would cause the reporting person's beneficial ownership, together with its affiliates, to exceed 9.99%.
THERALINK TECHNOLOGIES, INC.
Report date November 29, 2022 · Filed February 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 10% O.I.D. Senior Secured Convertible DebentureSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-11-29 | Direct | Not disclosed |
Reported balance
After 2022-11-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-29 · Other · Acquired Not disclosed · Balance Not disclosed F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F2: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F4: Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock. |
| 10% O.I.D. Senior Secured Convertible DebentureSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-11-29 | Direct | Not disclosed |
Reported balance
After 2022-11-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-29 · Grant · Acquired Not disclosed · Balance Not disclosed F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F4: Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock. |
| 10% O.I.D. Senior Secured Convertible DebentureSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-11-29 | Direct | Not disclosed |
Reported balance
After 2023-04-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-22 · Grant · Acquired Not disclosed · Balance Not disclosed F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-05-29 | Direct | 88,424,286 |
Reported balance
After 2022-11-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-29 · Other · Acquired 88,424,286 · Balance 88,424,286 F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F2: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F5: Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-05-29 | Direct | 15,714,286 |
Reported balance
After 2022-11-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-29 · Grant · Acquired 15,714,286 · Balance 15,714,286 F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F6: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $55,000 and 15,714,286 Warrants for an aggregate purchase price of $50,000 in a private placement offering that closed on November 29, 2022. F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F5: Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-05-29 | Direct | 44,314,286 |
Reported balance
After 2023-04-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-04-22 · Grant · Acquired 44,314,286 · Balance 44,314,286 F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F7: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $155,100 and 44,314,286 Warrants for an aggregate purchase price of $141,000 in a private placement offering that closed on April 22, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively.
F2: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person.
F3: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024.
F4: Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock.
F5: Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with.
F6: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $55,000 and 15,714,286 Warrants for an aggregate purchase price of $50,000 in a private placement offering that closed on November 29, 2022.
F7: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $155,100 and 44,314,286 Warrants for an aggregate purchase price of $141,000 in a private placement offering that closed on April 22, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2025 Filed Feb 27, 2025 20:49 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 23,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-018541 · tm257884-1_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,015 Underlying: Common Stock · 23,613 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 26, 2025, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2024 and February 26, 2025 and 50% of the LTIP Units will vest on February 26, 2026 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 16:27 UTC | IMAC Holdings, Inc. BACK · Entity 81795 | GrantCommon Stock, no par value | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-000072 · ownership.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 F1 · price: The Reporting Person received shares of common stock granted under the Issuer's 2018 Incentive Compensation Plan constituting annual board compensation with respect Reporting Person's service as a director during 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 16:06 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 29,384 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027016 · tm247073-2_4seq1.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 721,402 Underlying: Common Stock · 29,384 shares Expires not disclosed F3 · security: Represents LTIP Units in the OP. The Issuer's Board of Directors determined that on February 21, 2024, 50% of the LTIP Units became vested and nonforfeitable on February 21, 2024 as a result of meeting certain market-based performance criteria as of December 31, 2023, and 50% of the LTIP Units will vest on February 21, 2025 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on August 4, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 16:06 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 62,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027016 · tm247073-2_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 692,018 Underlying: Common Stock · 62,176 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. All of the LTIP Units vest on February 21, 2027, subject to the Reporting Person's continued employment on such date. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.2 to the Issuer's Quarterly Report on Form 10-Q filed on May 5, 2023. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| April 22, 2023 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | GrantCommon Stock Purchase Warrant · Derivative | 44,314,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 6 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,314,286 Underlying: Common Stock · 44,314,286 shares Expires 2029-05-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F7 · kind: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $155,100 and 44,314,286 Warrants for an aggregate purchase price of $141,000 in a private placement offering that closed on April 22, 2023. F7 · price: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $155,100 and 44,314,286 Warrants for an aggregate purchase price of $141,000 in a private placement offering that closed on April 22, 2023. Read SEC document |
| April 22, 2023 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | Grant10% O.I.D. Senior Secured Convertible Debenture · Derivative | Not disclosed | $141,000.00 Strike: $0.00 | $155,100.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 3 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 51,700,000 shares Expires 2023-11-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F3 · derivative.exercise_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F3 · derivative.expiration_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. Read SEC document |
| February 28, 2023 Filed Feb 28, 2023 19:18 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 13,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026874 · tm238076-1_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 629,842 Underlying: Common Stock · 13,175 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 28, 2023, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2022 and February 28, 2023 and 50% of the LTIP Units will vest on February 28, 2024 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on May 6, 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 18:20 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 36,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025453 · tm237802-1_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,667 Underlying: Common Stock · 36,563 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. All of the LTIP Units vest on February 23, 2026, subject to the Reporting Person's continued employment on such date. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.3 to the Issuer's Quarterly Report on Form 10-Q filed on May 6, 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| November 29, 2022 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | GrantCommon Stock Purchase Warrant · Derivative | 15,714,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 5 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,714,286 Underlying: Common Stock · 15,714,286 shares Expires 2029-05-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F6 · kind: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $55,000 and 15,714,286 Warrants for an aggregate purchase price of $50,000 in a private placement offering that closed on November 29, 2022. F6 · price: The Reporting Person purchased a 10% O.I.D. Senior Secured Convertible Debenture in the principal amount of $55,000 and 15,714,286 Warrants for an aggregate purchase price of $50,000 in a private placement offering that closed on November 29, 2022. F3 · derivative.exercise_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F5 · derivative.expiration_date: Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with. Read SEC document |
| November 29, 2022 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | OtherCommon Stock Purchase Warrant · Derivative | 88,424,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 4 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,424,286 Underlying: Common Stock · 88,424,286 shares Expires 2029-05-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F2 · kind: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F2 · price: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F3 · derivative.exercise_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F5 · derivative.expiration_date: Expiration Date in the event a Qualified Offering is not consummated prior to the maturity date of the debentures the Warrants are issued in connection with. Read SEC document |
| November 29, 2022 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | Grant10% O.I.D. Senior Secured Convertible Debenture · Derivative | Not disclosed | $50,000.00 Strike: $0.00 | $55,000.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 18,333,333 shares Expires 2023-11-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F3 · derivative.exercise_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F3 · derivative.expiration_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F4 · derivative.underlying_shares: Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock. Read SEC document |
| November 29, 2022 Filed Feb 2, 2024 20:10 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | Other10% O.I.D. Senior Secured Convertible Debenture · Derivative | Not disclosed | $0.00 Strike: $0.00 | $309,485.00 |
DisclosureSEC source: 0001493152-24-004817 · ownership.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 103,161,667 shares Expires 2023-11-29 F1 · derivative.exercise_price: Assumes a fixed conversion price of $0.003, but such conversion price is subject to adjustment as set forth in the debenture and warrant, respectively. F2 · kind: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F2 · price: The Reporting Person was issued a 10% Original Issue Discount ("O.I.D.") Senior Secured Convertible Debenture in the principal amount of $309,485 and 88,424,286 warrants in exchange for a demand promissory note in the principal amount of $250,000 previously issued to the Reporting Person. F3 · derivative.exercise_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F3 · derivative.expiration_date: The debentures and warrants acquired by the Reporting Person are subject to mandatory conversion upon the occurrence of certain events, as outlined in the debentures and warrants. The original maturity date of the debentures was subsequently extended to February 29, 2024. F4 · derivative.underlying_shares: Excludes shares issuable at the election of the Reporting Person upon conversion of accrued interest (both past and future) into shares of common stock. Read SEC document |
| September 16, 2022 Filed Sep 21, 2022 18:27 UTC | THERALINK TECHNOLOGIES, INC. THER · Entity 94673 | GrantStock Option (right to buy) · Derivative | 469,738,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-026509 · ownership.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,738,712 Underlying: Common Stock · 469,738,712 shares Expires 2032-09-16 F1 · derivative.exercise_date: 375,790,967 of the stock options will become exercisable upon the filing by the corporation of an S-8 registration statement covering its 2022 Equity Incentive Plan. The remaining 93,947,745 stock options will vest on May 1, 2023. Read SEC document |
| March 04, 2022 Filed Mar 4, 2022 19:11 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 27,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-030737 · tm228477-5_4seq1.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,104 Underlying: Common Stock · 27,698 shares Expires not disclosed F1 · security: The Issuer's Board of Directors determined on February 24, 2022 that 50% of the LTIP Units vested and became nonforfeitable on March 4, 2022 as a result of meeting certain market-based criteria as of March 4, 2022 and 50% of the LTIP Units will vest on March 4, 2023, pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on March 7, 2019. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 19:11 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 2,000 | $15.55 | $31,100.00 |
DisclosureSEC source: 0001104659-22-030737 · tm228477-5_4seq1.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,490 Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 17:59 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 18,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-028822 · tm228091-5_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,406 Underlying: Common Stock · 18,116 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined that on February 28, 2022, 50% of the LTIP Units will become vested and nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2021 and February 28, 2022 and 50% of the LTIP Units will vest on February 28, 2023 pursuant to the grant award agreement stipulations. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.1 to the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 21:34 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 14,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027519 · tm227785-2_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,290 Underlying: Common Stock · 14,858 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. All of the LTIP Units vest on February 24, 2025, subject to the Reporting Person's continued employment on such date. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.3 to the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 17:13 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 1,000 | $15.01 | $15,010.00 |
DisclosureSEC source: 0001104659-21-108231 · tm2125636-1_4seq1.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,490 Read SEC document |
| May 26, 2021 Filed May 28, 2021 16:36 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 8,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-074227 · tm2117936-10_4seq1.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,432 Underlying: Common Stock · 8,890 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. All of the LTIP Units vest on March 3, 2024, subject to the Reporting Person's continued employment on such date. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 10.3 to the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan (as amended from time to time) and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 17:52 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 1,000 | $13.81 | $13,810.00 |
DisclosureSEC source: 0001104659-21-033904 · tm219207d1_4seq1.xml · nonDerivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,490 Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 17:52 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 750 | $13.81 | $10,357.50 |
DisclosureSEC source: 0001104659-21-033904 · tm219207d1_4seq1.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,490 Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:45 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 39,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-031753 · tm218678d5_form4.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,542 Underlying: Common Stock · 39,680 shares Expires not disclosed F3 · security: The Issuer's Board of Directors determined on March 2, 2021 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of March 1, 2021 and 50% of the LTIP Units will vest on March 2, 2022, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to the Issuer's 2016 Equity Incentive Plan. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 21:45 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 34,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-031753 · tm218678d5_form4.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,862 Underlying: Common Stock · 34,759 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 2, 2021 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market-based performance criteria as of December 31, 2021 and 50% of the LTIP Units will vest on March 2, 2022, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to the Issuer's 2016 Equity Incentive Plan. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 16:05 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 10,000 | $13.39 | $133,900.00 |
DisclosureSEC source: 0001104659-20-092715 · tm2027145d1_form4.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,740 Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 16:07 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit · Derivative | 191,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-082726 · tm2024539d1_form4.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,103 Underlying: Common Stock · 191,205 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer, that were granted to the Reporting Person under the Issuer's 2016 Equity Incentive Plan (as amended from time to time) on July 9, 2020. The LTIP Units vest in equal one-fourth installments on the first four anniversaries of the grant date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock of the Issuer on a one-for-one basis. The LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock of the Issuer on a one-for-one basis. The LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock of the Issuer on a one-for-one basis. The LTIP Units have no expiration date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:28 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 51,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-029820 · tm2011902-2_form4.xml · derivative · entry 3 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,898 Underlying: Common Stock · 51,950 shares Expires not disclosed F4 · security: The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of February 28, 2020 and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on March 6, 2017, and pursuant to the Issuer's 2016 Equity Incentive Plan. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:28 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 6,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-029820 · tm2011902-2_form4.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,948 Underlying: Common Stock · 6,415 shares Expires not disclosed F3 · security: LTIP Units vest in equal one-third installments on March 3 of 2021, 2022 and 2023. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 5, 2020, and pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:28 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 20,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-029820 · tm2011902-2_form4.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,533 Underlying: Common Stock · 20,199 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2019 and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit annual award vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 7, 2019, and pursuant to the Issuer's 2016 Equity Incentive Plan. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 17:13 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-012800 · tv515757_form4.xml · derivative · entry 3 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,334 Underlying: Common Stock · 4,500 shares Expires not disclosed F5 · security: 50% of the LTIP Units vested at issuance and the remaining will vest on March 5, 2020 pursuant to the grant award agreement stipulations. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F5 · date: 50% of the LTIP Units vested at issuance and the remaining will vest on March 5, 2020 pursuant to the grant award agreement stipulations. F5 · shares: 50% of the LTIP Units vested at issuance and the remaining will vest on March 5, 2020 pursuant to the grant award agreement stipulations. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 17:13 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 9,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-012800 · tv515757_form4.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,834 Underlying: Common Stock · 9,136 shares Expires not disclosed F4 · security: LTIP Units vest in equal one-third installments on March 5 of 2020, 2021 and 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F4 · date: LTIP Units vest in equal one-third installments on March 5 of 2020, 2021 and 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F4 · shares: LTIP Units vest in equal one-third installments on March 5 of 2020, 2021 and 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 17:13 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 18,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-012800 · tv515757_form4.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,698 Underlying: Common Stock · 18,382 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 5, 2019 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2018 and 50% of the LTIP Units will vest on March 5, 2020, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F3 · date: Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on April 12, 2018. F3 · shares: Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on April 12, 2018. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| August 20, 2018 Filed Oct 10, 2018 06:05 UTC | Avant Diagnostics, Inc AVDX · Entity 148455 | GrantSeries A Preferred Stock · Derivative | 50,000 | $1.00 | $50,000.00 |
DisclosureSEC source: 0001493152-18-014305 · ownership.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · Not disclosed shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer. F1 · derivative.exercise_date: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer. F1 · derivative.expiration_date: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer. F1 · derivative.underlying_shares: The Reporting Person purchased the Series A Preferred Stock from the Company on August 20, 2018. The Series A Preferred Stock has no expiration date and upon consummation of a reverse stock split of the Issuer's common stock such that after consummation of such reverse stock split there are approximately 15,000,000 shares of the Issuer's common stock outstanding, the holders shall take all necessary steps with the Issuer to exchange all outstanding shares of Series A Preferred Stock into shares of the Issuer's common stock at a rate to be agreed upon between the parties. The holders of Series A Preferred Stock collectively shall always constitute 50.1% of the voting power of the Issuer. Read SEC document |
| March 13, 2018 Filed Mar 13, 2018 16:53 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 2,000 | $7.20 | $14,400.00 |
DisclosureSEC source: 0001144204-18-014405 · tv488435_form4.xml · nonDerivative · entry 3 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,740 Read SEC document |
| March 13, 2018 Filed Mar 13, 2018 16:53 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 2,000 | $7.06 | $14,120.00 |
DisclosureSEC source: 0001144204-18-014405 · tv488435_form4.xml · nonDerivative · entry 2 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,740 Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 16:53 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 2,000 | $7.12 | $14,240.00 |
DisclosureSEC source: 0001144204-18-014405 · tv488435_form4.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,740 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 20:09 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 13,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-013433 · tv488020_form4.xml · derivative · entry 2 Busch Jeffrey · CIK 0001620772 · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,316 Underlying: Common Stock · 13,111 shares Expires not disclosed F4 · security: LTIP Units vest in equal one-third installments on March 5 of 2019, 2020 and 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F4 · date: LTIP Units vest in equal one-third installments on March 5 of 2019, 2020 and 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F4 · shares: LTIP Units vest in equal one-third installments on March 5 of 2019, 2020 and 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 20:09 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit (Right to Buy) · Derivative | 9,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-013433 · tv488020_form4.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,205 Underlying: Common Stock · 9,730 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 5, 2018 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2017 and 50% of the LTIP Units will vest on December 31, 2018, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F3 · date: Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.1 to the Issuer's Current Report on Form 8-K filed on March 6, 2017. F3 · shares: Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.1 to the Issuer's Current Report on Form 8-K filed on March 6, 2017. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 07:13 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 2,630 | $9.29 | $24,432.70 |
DisclosureSEC source: 0001533615-17-000012 · primary_doc.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,740 Read SEC document |
| October 11, 2017 Filed Oct 12, 2017 16:05 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Units · Derivative | 32,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001533615-17-000011 · primary_doc.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,475 Underlying: Common Stock · 32,787 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units that have reached capital account parity with common units in the OP may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F3 · shares: LTIP Units vest in equal one-half installments on October 11 of 2018 and 2019. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units that have reached capital account parity with common units in the OP may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units that have reached capital account parity with common units in the OP may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 10:53 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | PurchaseCommon Stock | 11,100 | $9.00 | $99,900.00 |
DisclosureSEC source: 0001533615-17-000003 · primary_doc.xml · nonDerivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,110 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 09:06 UTC | Chiron Real Estate Inc. GMRE · Entity 5421 | GrantLTIP Unit · Derivative | 8,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001533615-16-000003 · primary_doc.xml · derivative · entry 1 Busch Jeffrey · CIK 0001620772 · Director · Chairman, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,688 Underlying: Common Stock · 8,688 shares Expires not disclosed F1 · security: Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. F2 · derivative.exercise_price: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F3 · shares: LTIP Units vest in equal one-third installments on December 21 of 2017, 2018 and 2019. F2 · derivative.exercise_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. F2 · derivative.expiration_date: As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.